Literature DB >> 17124423

Daptomycin clearance during modeled continuous renal replacement therapy.

Mariann D Churchwell1, Deborah A Pasko, Bruce A Mueller.   

Abstract

BACKGROUND/AIMS: Pharmacotherapy in critically ill patients receiving continuous renal replacement therapies (CRRT) is challenging due to the lack of published information to base dosing regimens.
METHODS: Daptomycin's transmembrane clearance during continuous hemofiltration and hemodialysis was assessed using an in vitro model with AN69 and polysulfone hemodiafilters at varying ultrafiltrate and dialysate flow rates (1, 2, 3 and 6 l/h).
RESULTS: During continuous hemofiltration, mean daptomycin sieving coefficient ranged from 0.14 to 0.20. Transmembrane clearances were significantly different between filter types for ultrafiltration rates of 2, 3 and 6 l/h. For continuous hemodialysis, mean daptomycin saturation coefficient ranged from 0.05 to 0.15. AN69-based daptomycin clearances were significantly lower than polysulfone values at dialysate flow rates of 2, 3 and 6 l/h.
CONCLUSION: The extent of daptomycin's transmembrane clearance is dependent on hemodiafilter type, dialysate and ultrafiltration rates. CRRT with high ultrafiltrate or dialysate rates may result in substantial daptomycin clearances.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17124423     DOI: 10.1159/000097078

Source DB:  PubMed          Journal:  Blood Purif        ISSN: 0253-5068            Impact factor:   2.614


  15 in total

1.  [Drug dosing in extracorporeal therapy].

Authors:  J T Kielstein
Journal:  Med Klin Intensivmed Notfmed       Date:  2014-05-22       Impact factor: 0.840

2.  Influence of hemodialysis on regadenoson clearance in an in vitro hemodialysis model.

Authors:  Katherine N Gharibian; Venkatesh L Murthy; Bruce A Mueller
Journal:  J Nucl Cardiol       Date:  2016-09-15       Impact factor: 5.952

Review 3.  Antibiotic dosing in critically ill patients with acute kidney injury.

Authors:  Rachel F Eyler; Bruce A Mueller
Journal:  Nat Rev Nephrol       Date:  2011-02-22       Impact factor: 28.314

4.  Reply to Baud and Houzé, "Should In Vitro and In Vivo Studies on Antimicrobial Agents during Continuous Renal Replacement Therapy Comply with General Principles of Pharmacokinetics?"

Authors:  E Wenzler; M Biagi; X Tan; D A Butler
Journal:  Antimicrob Agents Chemother       Date:  2020-05-21       Impact factor: 5.191

5.  Experience with daptomycin daily dosing in ICU patients undergoing continuous renal replacement therapy.

Authors:  B Preiswerk; A Rudiger; J Fehr; N Corti
Journal:  Infection       Date:  2012-07-21       Impact factor: 3.553

6.  Longitudinal hemodiafilter performance in modeled continuous renal replacement therapy.

Authors:  Deborah A Pasko; Mariann D Churchwell; Noha N Salama; Bruce A Mueller
Journal:  Blood Purif       Date:  2011-03-02       Impact factor: 2.614

7.  Pharmacokinetics of Commonly Used Medications in Children Receiving Continuous Renal Replacement Therapy: A Systematic Review of Current Literature.

Authors:  Samuel Dubinsky; Kevin Watt; Steven Saleeb; Bilal Ahmed; Caitlin Carter; Cindy H T Yeung; Andrea Edginton
Journal:  Clin Pharmacokinet       Date:  2021-11-30       Impact factor: 6.447

8.  Acetaminophen clearance during ex vivo continuous renal replacement therapies.

Authors:  Bridget A Scoville; Vera Vulaj; Bruce A Mueller; Gail M Annich; Deborah S Wagner
Journal:  J Artif Organs       Date:  2017-10-23       Impact factor: 1.731

9.  Ex vivo Rezafungin Adsorption and Clearance During Continuous Renal Replacement Therapy.

Authors:  Soo Min Jang; Grayson Hough; Bruce A Mueller
Journal:  Blood Purif       Date:  2018-06-14       Impact factor: 2.614

10.  Etanercept clearance during an in vitro model of continuous venovenous hemofiltration.

Authors:  Geoffrey M Fleming; Noha N Salama; Saada K Eid; Kenneth R Cooke; Bruce A Mueller
Journal:  Blood Purif       Date:  2009-09-01       Impact factor: 2.614

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.